Ulcerative Colitis
Stories
-
Janssen posts Phase 3 ustekinumab results in pediatric ulcerative colitis
Janssen Research & Development, LLC posted results of a Phase 3 ustekinumab study in 112 participants with moderately to severely active ulcerative colitis. The record lists 25 percent in clinical remission at induction Week 8.
-
Janssen posts results of Phase 3 ustekinumab trial in pediatric ulcerative colitis
The study, completed in 2025, enrolled 112 pediatric participants with moderately to severely active ulcerative colitis and evaluated ustekinumab induction and maintenance therapy. Results were first posted on ClinicalTrials.gov on October 20, 2026.